When faced with unprecedented time constraints and high volume, innovative ideas and core partnerships are key. This is especially true for the Regulatory and Clinical portfolios, which require local language translation of more than 40,000 documents a year to enable successful authorisation.

As a solution, a leading pharmaceutical corporation and trusted partner RWS collaborated on the introduction of bespoke machine translation, supplemented by efficient operating procedures, high-performing human linguists, QA tools and translation assets.

To read more, please download this free white paper.